The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Lopinavir     (2S)-N-[(2R,4S,5S)-5-[2- (2,6...

Synonyms: Aluviran, Koletra, CHEMBL729, ABT-378, SureCN21775, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Aluviran


High impact information on Aluviran


Chemical compound and disease context of Aluviran


Biological context of Aluviran


Anatomical context of Aluviran


Associations of Aluviran with other chemical compounds


Gene context of Aluviran


Analytical, diagnostic and therapeutic context of Aluviran


  1. Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children. van der Lee, M., Verweel, G., de Groot, R., Burger, D. Antivir. Ther. (Lond.) (2006) [Pubmed]
  2. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Raguin, G., Chêne, G., Morand-Joubert, L., Taburet, A.M., Droz, C., Le Tiec, C., Clavel, F., Girard, P.M. Antivir. Ther. (Lond.) (2004) [Pubmed]
  3. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. Rodés, B., Toro, C., Sheldon, J.A., Jiménez, V., Mansinho, K., Soriano, V. AIDS (2006) [Pubmed]
  4. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. McKinnon, J.E., Arribas, J.R., Pulido, F., Delgado, R., Mellors, J.W. AIDS (2006) [Pubmed]
  5. Remission of HIV-associated myelopathy after initiation of lopinavir in a patient with extensive previous exposure to highly active antiretroviral therapy. Eyer-Silva, W.A., Couto-Fernandez, J.C., Caetano, M.R., Chequer-Fernandez, S.L., Pinto, J.F., Morais-De-Sá, C.A., Morgado, M.G. AIDS (2002) [Pubmed]
  6. Low genetic barrier to large increases in HIV-1 cross-resistance to protease inhibitors during salvage therapy. Morand-Joubert, L., Charpentier, C., Poizat, G., Chêne, G., Dam, E., Raguin, G., Taburet, A.M., Girard, P.M., Hance, A.J., Clavel, F. Antivir. Ther. (Lond.) (2006) [Pubmed]
  7. Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected children. Fraaij, P.L., Neubert, J., Bergshoeff, A.S., van Rossum, A.M., Hartwig, N.G., Schroten, H., Korn, K., Burger, D.M., de Groot, R., Niehues, T. Antivir. Ther. (Lond.) (2004) [Pubmed]
  8. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks. Murphy, R.L. Antivir. Ther. (Lond.) (1999) [Pubmed]
  9. Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity: demonstrable differences in vitro and clinically. Noor, M.A., Flint, O.P., Maa, J.F., Parker, R.A. AIDS (2006) [Pubmed]
  10. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. Murphy, R.L., Brun, S., Hicks, C., Eron, J.J., Gulick, R., King, M., White, A.C., Benson, C., Thompson, M., Kessler, H.A., Hammer, S., Bertz, R., Hsu, A., Japour, A., Sun, E. AIDS (2001) [Pubmed]
  11. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Ribera, E., Lopez, R.M., Diaz, M., Pou, L., Ruiz, L., Falcó, V., Crespo, M., Azuaje, C., Ruiz, I., Ocaña, I., Clotet, B., Pahissa, A. Antimicrob. Agents Chemother. (2004) [Pubmed]
  12. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens. Loutfy, M.R., Raboud, J.M., Walmsley, S.L., Saskin, R., Montaner, J.S., Hogg, R.S., Thompson, C.A., Harrigan, P.R. Antivir. Ther. (Lond.) (2004) [Pubmed]
  13. Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy. Khanlou, H., Graham, E., Brill, M., Farthing, C. AIDS (2002) [Pubmed]
  14. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. van der Lee, M.J., Dawood, L., ter Hofstede, H.J., de Graaff-Teulen, M.J., van Ewijk-Beneken Kolmer, E.W., Caliskan-Yassen, N., Koopmans, P.P., Burger, D.M. Clin. Pharmacol. Ther. (2006) [Pubmed]
  15. Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial. Eron, J.J., Feinberg, J., Kessler, H.A., Horowitz, H.W., Witt, M.D., Carpio, F.F., Wheeler, D.A., Ruane, P., Mildvan, D., Yangco, B.G., Bertz, R., Bernstein, B., King, M.S., Sun, E. J. Infect. Dis. (2004) [Pubmed]
  16. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Cvetkovic, R.S., Goa, K.L. Drugs (2003) [Pubmed]
  17. Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations. Gutiérrez, F., Padilla, S., Masiá, M., Navarro, A., Gallego, J., Hernández, I., Ramos, J.M., Martin-Hidalgo, A. Antivir. Ther. (Lond.) (2004) [Pubmed]
  18. Human immunodeficiency virus protease inhibitors accumulate into cultured human adipocytes and alter expression of adipocytokines. Vernochet, C., Azoulay, S., Duval, D., Guedj, R., Cottrez, F., Vidal, H., Ailhaud, G., Dani, C. J. Biol. Chem. (2005) [Pubmed]
  19. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. Jain, R.G., Lenhard, J.M. J. Biol. Chem. (2002) [Pubmed]
  20. Limited penetration of lopinavir into seminal plasma of HIV-1-infected men. Sankatsing, S.U., Droste, J., Burger, D., Van Praag, R.M., Jurriaans, S., Lange, J.M., Prins, J.M. AIDS (2002) [Pubmed]
  21. Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. Capparelli, E.V., Holland, D., Okamoto, C., Gragg, B., Durelle, J., Marquie-Beck, J., van den Brande, G., Ellis, R., Letendre, S. AIDS (2005) [Pubmed]
  22. Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen. Ribera, E., Azuaje, C., Lopez, R.M., Diaz, M., Feijoo, M., Pou, L., Crespo, M., Curran, A., Ocaña, I., Pahissa, A. AIDS (2006) [Pubmed]
  23. Differential effect of HIV protease inhibitors on adipogenesis: intracellular ritonavir is not sufficient to inhibit differentiation. Vernochet, C., Azoulay, S., Duval, D., Guedj, R., Ailhaud, G., Dani, C. AIDS (2003) [Pubmed]
  24. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. Sulkowski, M.S., Mehta, S.H., Chaisson, R.E., Thomas, D.L., Moore, R.D. AIDS (2004) [Pubmed]
  25. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. Crane, H.M., Van Rompaey, S.E., Kitahata, M.M. AIDS (2006) [Pubmed]
  26. Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. Weemhoff, J.L., von Moltke, L.L., Richert, C., Hesse, L.M., Harmatz, J.S., Greenblatt, D.J. J. Pharm. Pharmacol. (2003) [Pubmed]
  27. The effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects. Adkison, K.K., Shachoy-Clark, A., Fang, L., Lou, Y., Otto, V.R., Berrey, M.M., Piscitelli, S.C. British journal of clinical pharmacology. (2006) [Pubmed]
  28. Kaletra (lopinavir/ritonavir). Corbett, A.H., Lim, M.L., Kashuba, A.D. The Annals of pharmacotherapy. (2002) [Pubmed]
  29. Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations. Bongiovanni, M., Bini, T., Adorni, F., Meraviglia, P., Capetti, A., Tordato, F., Cicconi, P., Chiesa, E., Cordier, L., Cargnel, A., Landonio, S., Rusconi, S., d'Arminio Monforte, A. Antivir. Ther. (Lond.) (2003) [Pubmed]
  30. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Dragsted, U.B., Gerstoft, J., Youle, M., Fox, Z., Losso, M., Benetucci, J., Jayaweera, D.T., Rieger, A., Bruun, J.N., Castagna, A., Gazzard, B., Walmsley, S., Hill, A., Lundgren, J.D. Antivir. Ther. (Lond.) (2005) [Pubmed]
  31. Accumulation of lopinavir resistance-associated mutations over 3 years follow-up of patients on highly active antiretroviral therapy: implication in salvage therapy. Tsuchiya, K., Matsuoka, S., Hachiya, A., Yasuoka, A., Tachikawa, N., Kikuchi, Y., Genka, I., Teruya, K., Kimura, S., Oka, S. AIDS (2001) [Pubmed]
  32. Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. Boffito, M., Back, D.J., Hoggard, P.G., Caci, A., Bonora, S., Raiteri, R., Sinicco, A., Reynolds, H.E., Khoo, S., Di Perri, G. AIDS (2003) [Pubmed]
WikiGenes - Universities